These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 20566574)

  • 21. The P2Y12 receptor as a therapeutic target in cardiovascular disease.
    Storey RF
    Platelets; 2001 Jun; 12(4):197-209. PubMed ID: 11454254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis.
    Schrör K
    Semin Thromb Hemost; 1997; 23(4):349-56. PubMed ID: 9263351
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibiting PAR-1 in the prevention and treatment of atherothrombotic events.
    Tomasello SD; Angiolillo DJ; Goto S
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1557-67. PubMed ID: 20979570
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
    Gurbel PA
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S20-8. PubMed ID: 17224887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving antiplatelet therapy for atherothrombotic disease: preclinical results with SCH 530348, the first oral thrombin receptor antagonist selective for PAR-1.
    Hildemann SK; Bode C
    Hamostaseologie; 2009 Nov; 29(4):349-55. PubMed ID: 19882073
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
    Serebruany VL; Malinin AI; Oshrine BR; Sane DC; Takserman A; Atar D; Hennekens CH
    Thromb Res; 2004; 113(3-4):197-204. PubMed ID: 15140583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. G-protein-coupled receptors as signaling targets for antiplatelet therapy.
    Smyth SS; Woulfe DS; Weitz JI; Gachet C; Conley PB; Goodman SG; Roe MT; Kuliopulos A; Moliterno DJ; French PA; Steinhubl SR; Becker RC;
    Arterioscler Thromb Vasc Biol; 2009 Apr; 29(4):449-57. PubMed ID: 19023091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet function in intravascular device implant-induced intimal injury.
    Tesfamariam B
    Cardiovasc Revasc Med; 2008; 9(2):78-87. PubMed ID: 18486081
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiplatelet therapy after implantation of drug-eluting stents: duration, resistance, alternatives, and management of surgical patients.
    Gurbel PA; DiChiara J; Tantry US
    Am J Cardiol; 2007 Oct; 100(8B):18M-25M. PubMed ID: 17950828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The genetics of antiplatelet drug resistance.
    Feher G; Feher A; Pusch G; Lupkovics G; Szapary L; Papp E
    Clin Genet; 2009 Jan; 75(1):1-18. PubMed ID: 19067731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of platelets and antiplatelet therapy in cardiovascular disease.
    Ueno M; Kodali M; Tello-Montoliu A; Angiolillo DJ
    J Atheroscler Thromb; 2011; 18(6):431-42. PubMed ID: 21427504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coronary atherothrombotic disease: progress in antiplatelet therapy.
    Badimon L; Vilahur G
    Rev Esp Cardiol; 2008 May; 61(5):501-13. PubMed ID: 18462654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL; Malinin AI; Pokov AN; Hanley DF
    Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of platelet recruitment by endothelial cell CD39/ecto-ADPase: significance for occlusive vascular diseases.
    Marcus AJ; Broekman MJ; Drosopoulos JH; Pinsky DJ; Islam N; Maliszewsk CR
    Ital Heart J; 2001 Nov; 2(11):824-30. PubMed ID: 11770867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet inhibitors and monitoring platelet function: implications for bleeding.
    Shore-Lesserson L
    Hematol Oncol Clin North Am; 2007 Feb; 21(1):51-63. PubMed ID: 17258118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiplatelet therapy and vascular disease: an update.
    Buch MH; Prendergast BD; Storey RF
    Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):249-75. PubMed ID: 21303843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiplatelet therapy: thrombin receptor antagonists.
    Tello-Montoliu A; Tomasello SD; Ueno M; Angiolillo DJ
    Br J Clin Pharmacol; 2011 Oct; 72(4):658-71. PubMed ID: 21906120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenosine diphosphate receptors on blood platelets: potential new targets for antiplatelet therapy.
    Rozalski M; Nocun M; Watala C
    Acta Biochim Pol; 2005; 52(2):411-5. PubMed ID: 15912207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current perspectives in the treatment of thrombotic disorders.
    Drouet L; Caen JP
    Semin Thromb Hemost; 1989 Apr; 15(2):111-22. PubMed ID: 2665082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.